FAX TRANSMISSION	AUG 3 1 2006
DATE: August 31, 2006	
PTO IDENTIFIER: Application Number 09/396,523-Conf. #7553 Patent Number	
Inventor: Christine L. O'Day et al.	
MESSAGE TO: US Patent and Trademark Office	
FAX NUMBER: (571) 273-8300	
FROM: CONNOLLY BOVE LODGE & HUTZ LLP	
Burton A. Amernick	
PHONE: (202) 331-7111	
Attorney Dkt. #: 22116-00005-US3	
PAGES (Including Cover Sheet): 11	
CONTENTS: Information Disclosure Statement (2 pages) IDS (Citation) by Applicant (1 Reference) (1 page) Cited Ref (6 pages) Certificate of Transmission (1 page)	
If your receipt of this transmission is in error, please notify this firm is collect call to sender at (202) 331-7111 and send the original transmis mail at the address below.	
This transmission is intended for the sole use of the individual and is addressed, and may contain information that is privileged, confexempt from disclosure under applicable law. You are hereby no dissemination, distribution or duplication of this transmission by than the intended addressee or its designated agent is strictly prol	idential and tified that any someone other
CONNOLLY BOVE LODGE & HUTZ LLP 1990 M Street, N.W., Suite 800, Washington, DC 20036 Telephone: (202) 331-7111 Facsimile:	

AUG 3 1 2006

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031

U. S. Patient and Tradamark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (16 keepers), COCCOC COC. Attorney Docket No.: 22116-00005-US3 Application No. (if known): 09/396,523

hereb States	y certify that this correspo Patent and Trademark O	ondence is bei ffice.	ng facsimile trans	mitted to the United
on	August 31, 2006 Date	_ ·		
	Typed or prin	Signatur Nicole Bro ted name of par	e wn son signing Certific	ate
Regi	stration Number, if applicable	e	Tele	phone Number
Note:	Each paper must have its identify each submitted pa	own certificate o per.	f transmission, or t	nis certificate must
	Information Disclosure S IDS (Citation) by Applica Cited Ref (6 pages)	Statement (2 p ant (1 Referen	ages) ce) (1 page)	
	Information Disclosure S IDS (Citation) by Applica	Statement (2 p	ages) ce) (1 page)	

RECEIVED CENTRAL FAX CENTER

AUG 3 1 2006

Docket No.: 22116-00005-US3

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Christine L. O'Day et al.

Application No.: 09/396,523

Confirmation No.: 7553

Filed: September 15, 1999

Art Unit: 1621

For:

NOVEL POLYAMINE ANALOGUES AS

THERAPEUTIC AND DIAGNOSTIC

AGENTS

Examiner: P. G. O'Sullivan

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the reference listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

AUG. 31. 2006 2:58PM CBL&H 202 293 6229 NO. 5382 P. 4

Application No.: 09/396,523 Docket No.: 22116-00005-US3

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed reference.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 22116-00005-US3.

Dated: August 31, 2006

Respectfully submitted,

Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE & HUTZ LLP

1990 M Street, N.W., Suite 800

Washington, DC 20036

(202) 331-7111 (Phone)

(202) 293-6229 (Fax)

Attorney for Applicant

AUG 3 1 2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1895, no persons are required to respond to a defection of information unless it contains a valid DMB control purpose.

Substitute for form 1449A/B/PTO				Complete if Known		
		Application Number	09/396,523-Conf. #7553			
INFORMATION DISCLOSURE		Fliing Date	September 15, 1999			
STATEMENT BY APPLICANT		First Named Inventor	Christine L. O'Day			
		Art Unit	1621			
(Use as many sheets as necessary)		Examiner Name	P. G. O'Sullivan			
Sheel	1	of	1	Attorney Docket Number	22116-00005-US3	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cita No.	Document Number Number-Kind Code ² (IF Innown)	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Cited Document	Pagos, Columna, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ³ (I' known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pagee, Columna, Lines, Where Relevant Passages or Relevant Figures Appear	₽*

"EXAMINER: Initial if reference considered, whether or not classion is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (options). \(^2\) See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901,04. \(^2\) Enter Office that leaved the document, by the two-letter code (WIPO Standard ST.3). \(^6\) For Japanese petent documents, the indication of the year of the reign of the Emperor must precede the serial number of the petent document. \(^4\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T³		
	CA	"The role of polyamine catabolism in polyamine analogue-induced programmed cell death" Ha et al., <i>Proc. Natl. Acad. Sci.</i> , Vol. 94, pages 11557-11562, October 1997.			

[&]quot;EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation If not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	I Date I "	
	logia [
Signature	Considered	
O-SI IGIGIO	Considered	

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is stisched.